搜索
LivaNova PLC
LIVN添加自选
82.230USD
-0.830-1.00%
收盘 06/30, 16:00（美东）报价延迟15分钟
4.51B总市值
41.59市盈率 TTM
关键数据
82.770今开
82.915最高
664.29K成交量
41.59市盈率 TTM
17.47市盈率动
--股息TTM
1.21%换手率
83.060昨收
80.740最低
42.24M成交额
71.39市盈率静
3.73市净率
0.00%股息率 TTM
4.22%ROA
75.81552周最高
0.65量比
63.23M净利润
54.90M总股本
1.9772每股收益TTM
0.87Beta
9.54%ROE
41.01552周最低
2.62%振幅
67.29%毛利率
4.51B总市值
6.49回报/风险
1.93%风险率
TradingKey LivaNova PLC股票评分
单位: USD 更新时间: 2026-06-29操作建议
LivaNova PLC当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在医疗设备与耗材行业排名24/204位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价81.54。中期看，股价处于上升通道。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
LivaNova PLC评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
LivaNova PLC亮点
亮点风险
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
业绩高增长
公司营业收入稳步增长，连续3年增长20.33%
业绩转亏
公司业绩转亏，最新年度亏损美元
估值高估
公司最新PE估值42.01，处于3年历史高位
机构减仓
最新机构持股60.49M股，环比减少15.69%
Hotchkis & Wiley持仓
明星投资者Hotchkis & Wiley持仓，最新持仓市值478.62K
分析师目标
根据
10
位分析师
买入
评级
81.544
目标均价
-1.83%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
LivaNova PLC新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
LivaNova PLC简介
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
公司代码LIVN
公司LivaNova PLC
CEOMakatsaria (Vladimir A)
网址https://www.livanova.com/
相关品种
-1.10%
-1.12%
-2.20%
-2.04%
-1.28%
-0.15%
-4.84%
-3.35%
-0.64%
-0.36%
-1.11%
-1.86%
+0.49%
-0.86%
+2.15%
-1.77%
-2.57%
-0.32%
-0.03%
-0.43%热门品种
常见问题
LivaNova PLC(LIVN)的当前股价是多少？
LivaNova PLC(LIVN)的当前股价是 82.23。
LivaNova PLC的股票代码是什么？
LivaNova PLC的股票代码是LIVN。
LivaNova PLC股票的52周最高点是多少？
LivaNova PLC股票的52周最高点是75.81。
LivaNova PLC股票的52周最低点是多少？
LivaNova PLC股票的52周最低点是41.02。
LivaNova PLC的市值是多少？
LivaNova PLC的市值是4.51B。
现在LivaNova PLC(LIVN)的股票是买入、持有还是卖出？
根据分析师评级，LivaNova PLC(LIVN)的总体评级为买入，目标价格为81.54。
LivaNova PLC(LIVN)股票的每股收益（EPS TTM）是多少
LivaNova PLC(LIVN)股票的每股收益（EPS TTM）是-4.45。
